Warren tells health chief Trump's promised drug price cuts are missing
Sen. Elizabeth WarrenElizabeth Ann WarrenReady for somebody? Dems lack heir apparent this time Obama meets with possible 2020 presidential contenders: report Five ways Mulvaney is cracking down on his own agency MORE (D-Mass.) pressed Health and Human Services (HHS) Secretary Alex Azar on Tuesday about why no drug companies have announced price decreases despite President TrumpDonald John TrumpSanford at risk in primary shadowed by Trump McConnell cements his standing in GOP history Ready for somebody? Dems lack heir apparent this time MORE saying they would soon.
Warren focused on Trump’s statement at the end of May that “in two weeks” drug companies would “announce voluntary massive drops in prices.” The two-week mark from that statement is this Wednesday.
“He said there would be massive decreases in prices within two weeks,” Warren said during a Senate Health Committee hearing. “It’s been two weeks and there have been no decreases and an indication of increase.”
Azar countered at the hearing that there are drug companies working on price decreases.
“There are actually several drug companies that are looking at substantial and material decreases in drug prices,” he said.
The health chief said the holdup is that negotiators known as pharmacy benefit managers (PBMs) are actually discouraging price decreases because that could reduce the amount of rebates that the PBMs get.
“Oddly, the fear is that they would be discriminated against for decreasing their price,” Azar said.
Warren, a liberal champion who is a possible 2020 presidential contender, did not buy that argument, saying, “In other words, the president’s promise that we would see massive decreases in two weeks hasn’t happened and you don’t have anyone lined up who’s actually going to decrease drug prices.”
The Hill reported Monday that HHS officials have been meeting with drug companies to encourage them to voluntarily reduce prices.
Azar has indicated he will act on his own if pharmaceutical companies do not agree to voluntary price decreases, but Democrats have attacked his plan as too soft on drug companies.
email@example.com (Peter Sullivan)